CMS is taking a significant step toward implementing its historic new power to negotiate Medicare drug prices under the Inflation Reduction Act by inviting drug makers to the first of a series of sessions on Part D price negotiations next Tuesday. The Dec. 1 invitation from CMS Medicare chief Meena Seshamani signals that despite the statute’s lack of implementation details and the agency’s authority to rely on guidance rather than the traditional rulemaking, CMS intends to take stakeholder feedback into...